AR066396A1 - Anticuerpos anti-r7v y usos de los mismos - Google Patents
Anticuerpos anti-r7v y usos de los mismosInfo
- Publication number
- AR066396A1 AR066396A1 ARP080101151A ARP080101151A AR066396A1 AR 066396 A1 AR066396 A1 AR 066396A1 AR P080101151 A ARP080101151 A AR P080101151A AR P080101151 A ARP080101151 A AR P080101151A AR 066396 A1 AR066396 A1 AR 066396A1
- Authority
- AR
- Argentina
- Prior art keywords
- sec
- cell
- antibodies
- hiv
- identity
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 abstract 5
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 241000238631 Hexapoda Species 0.000 abstract 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 abstract 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000033581 fucosylation Effects 0.000 abstract 1
- 102000054751 human RUNX1T1 Human genes 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 210000005253 yeast cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Anticuerpos humanos con capacidad de unirse específicamente al epítope R7V del HIV. Todos estos anticuerpos tienen CDR humanas y son capaces de neutralizar específicamente todas las cepas del HIV, incluyendo mutantes de escape. Estos anticuerpos son utiles para el tratamiento de la infeccion por HIV, especialmente en pacientes con fracaso de la HAART. Reivindicacion 1: Un anticuerpo aislado, o uno de sus fragmentos funcionales, donde dicho anticuerpo o uno de sus fragmentos mencionados tiene la capacidad de unirse específicamente al epítope R7V (RTPKIQV - SEC. ID. N°: 11) y la capacidad de neutralizar cepas de HIV, que comprende: i) una cadena liviana que comprende las regiones determinantes de la complementariedad CDR que comprenden la secuencia de aminoácidos de SEC. ID. N°: 1 (QSVLYSSNNKNY), SEC. ID. N°: 2 (WAS) y SEC. ID. N°: 3 (QQYYSTPQT), o CDR cuyas secuencias tienen por lo menos 80 %, preferentemente 90 % de identidad, tras la alineacion optima, con la SEC. ID. N°: 1, 2 o 3 y ii) una cadena pesada que comprende las CDR que comprenden la secuencia de aminoácidos de SEC. ID. N°: 6 (GGSISSYY), SEC. ID. N° 7 (IYYSGST) y SEC. ID. N° 8 (ARGRSWFSY), o las CDR cuyas secuencias tienen por lo menos 80 %, preferentemente 90 % de identidad, tras la alineacion optima, con la SEC. ID N°: 6, 7 y 8. Reivindicacion 6: Un ácido nucleico aislado que comprende una secuencia que tiene por lo menos 80 %, preferentemente 90 % de identidad, tras la alineacion optima, con la secuencia SEC. ID. N°: 5. Reivindicacion 8: Un vector que comprende un ácido nucleico de acuerdo con lo definido en la reivindicacion 6 o 7. Reivindicacion 10: Una célula huésped transformada con un vector de acuerdo con la reivindicacion 8 o 9 o que comprende el mismo. Reivindicacion 11: Una célula huésped de acuerdo con la reivindicacion 10, que es una célula de insectos tal como una célula Sf9, una célula bacteriana, una célula de levadura, una célula animal, especialmente una célula de mamífero tal como linfocitos B inmortalizados con EBV, CHO, CHO genéticamente modificadas para producir anticuerpos con baja fucosilacion, o YB2/0.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89635907P | 2007-03-22 | 2007-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066396A1 true AR066396A1 (es) | 2009-08-19 |
Family
ID=39473318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101151A AR066396A1 (es) | 2007-03-22 | 2008-03-19 | Anticuerpos anti-r7v y usos de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20110123536A1 (es) |
| EP (1) | EP2137214A1 (es) |
| JP (1) | JP2010521189A (es) |
| KR (1) | KR20100014495A (es) |
| CN (1) | CN101679515A (es) |
| AR (1) | AR066396A1 (es) |
| AU (1) | AU2008228246A1 (es) |
| BR (1) | BRPI0808287A2 (es) |
| CA (1) | CA2681130A1 (es) |
| CL (1) | CL2008000820A1 (es) |
| IL (1) | IL201034A0 (es) |
| MA (1) | MA31256B1 (es) |
| MX (1) | MX2009009982A (es) |
| RU (1) | RU2009138922A (es) |
| TN (1) | TN2009000380A1 (es) |
| TW (1) | TW200846363A (es) |
| WO (1) | WO2008113833A1 (es) |
| ZA (1) | ZA200906516B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108117586A (zh) | 2010-08-10 | 2018-06-05 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| EP2715352B1 (en) * | 2011-05-31 | 2019-04-24 | Biogen MA Inc. | Method of assessing risk of pml |
| EP3004334A4 (en) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | METHOD FOR ASSESSING A PML RISK |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| SG10202010936RA (en) | 2014-02-21 | 2020-12-30 | Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| CN105020678B (zh) * | 2015-08-04 | 2017-10-13 | 珠海金晟照明科技有限公司 | 透镜单元、透镜组件和路灯灯头 |
| CA3021047A1 (en) | 2016-05-09 | 2017-11-16 | Icahn School Of Medicine At Mount Sinai | Broadly neutralizing anti-human cytomegalovirus (hcmv) antibodies and methods of use thereof |
| WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| EP3774890A4 (en) * | 2018-03-26 | 2022-05-04 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TARGETING OF C-TYPE LECTIN FROM SINUSOIDAL ENDOTHELIAL CELLS OF THE LIVER AND LYMPH NODES (LSECTIN) |
| WO2021212021A2 (en) * | 2020-04-16 | 2021-10-21 | Dana-Farber Cancer Institute, Inc. | Coronavirus antibodies and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030021800A1 (en) * | 1995-06-30 | 2003-01-30 | Jean-Claude Chermann | Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis |
| FR2735984B1 (fr) * | 1995-06-30 | 1997-09-19 | Inst Nat Sante Rech Med | Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic |
| FR2836146B1 (fr) * | 2002-02-15 | 2005-01-07 | Urrma R & D | IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS |
-
2008
- 2008-03-17 TW TW097109297A patent/TW200846363A/zh unknown
- 2008-03-19 KR KR1020097019607A patent/KR20100014495A/ko not_active Application Discontinuation
- 2008-03-19 JP JP2009554021A patent/JP2010521189A/ja active Pending
- 2008-03-19 BR BRPI0808287-1A2A patent/BRPI0808287A2/pt not_active IP Right Cessation
- 2008-03-19 AU AU2008228246A patent/AU2008228246A1/en not_active Abandoned
- 2008-03-19 WO PCT/EP2008/053317 patent/WO2008113833A1/en active Application Filing
- 2008-03-19 MX MX2009009982A patent/MX2009009982A/es not_active Application Discontinuation
- 2008-03-19 CN CN200880016515A patent/CN101679515A/zh active Pending
- 2008-03-19 AR ARP080101151A patent/AR066396A1/es not_active Application Discontinuation
- 2008-03-19 CA CA002681130A patent/CA2681130A1/en not_active Abandoned
- 2008-03-19 US US12/531,843 patent/US20110123536A1/en not_active Abandoned
- 2008-03-19 RU RU2009138922/10A patent/RU2009138922A/ru not_active Application Discontinuation
- 2008-03-19 EP EP08718038A patent/EP2137214A1/en not_active Withdrawn
- 2008-03-20 CL CL200800820A patent/CL2008000820A1/es unknown
-
2009
- 2009-09-17 IL IL201034A patent/IL201034A0/en unknown
- 2009-09-18 TN TNP2009000380A patent/TN2009000380A1/fr unknown
- 2009-09-18 MA MA32224A patent/MA31256B1/fr unknown
- 2009-09-18 ZA ZA200906516A patent/ZA200906516B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010521189A (ja) | 2010-06-24 |
| BRPI0808287A2 (pt) | 2014-10-07 |
| WO2008113833A1 (en) | 2008-09-25 |
| IL201034A0 (en) | 2010-05-17 |
| RU2009138922A (ru) | 2011-04-27 |
| AU2008228246A1 (en) | 2008-09-25 |
| CA2681130A1 (en) | 2008-09-25 |
| EP2137214A1 (en) | 2009-12-30 |
| TW200846363A (en) | 2008-12-01 |
| ZA200906516B (en) | 2010-05-26 |
| MA31256B1 (fr) | 2010-03-01 |
| US20110123536A1 (en) | 2011-05-26 |
| KR20100014495A (ko) | 2010-02-10 |
| MX2009009982A (es) | 2010-03-04 |
| TN2009000380A1 (en) | 2010-12-31 |
| CN101679515A (zh) | 2010-03-24 |
| CL2008000820A1 (es) | 2008-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066396A1 (es) | Anticuerpos anti-r7v y usos de los mismos | |
| MY194764A (en) | Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof | |
| EA202191751A1 (ru) | Гуманизированное антитело против pd-1 человека | |
| EA201390874A1 (ru) | Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение | |
| EA201170204A1 (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| AR082149A1 (es) | Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso | |
| AR059604A1 (es) | Anticuerpos contra il- 22 humana y usos para los mismos | |
| AR074563A1 (es) | Anticuerpos anti ligando 1 de muerte programada (anti-pd-l1) y su uso para mejorar la funcion de las celulas t | |
| BR112018075737A2 (pt) | anticorpo, composição, célula isolada, e, métodos para tratar câncer ou infecção em um paciente e para detectar expressão de pd-l1 em uma amostra. | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| GT201100023A (es) | Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos | |
| CY1114271T1 (el) | Αντισωματα εξουδετερωσης, ανθρωπινου κυτταρομεγαλοϊου και χρηση αυτων | |
| EA201201116A1 (ru) | Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а | |
| BR112012021329A2 (pt) | anticorpo monoclonal anti-tnf-<244> completamente humano, método de preparação e uso do mesmo. | |
| RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
| ES2721882T3 (es) | Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas | |
| GT201300149A (es) | Proteinas de union al tnf-a | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| NO20090069L (no) | Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse | |
| BR112012012912A2 (pt) | anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra. | |
| EA201490433A1 (ru) | Новое антитело против ngf человека | |
| PE20180576A1 (es) | ANTICUERPOS MONOCLONALES ESPECIFICOS PARA EL ANTIGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, UTILES PARA LA DETECCION Y EL DIAGNOSTICO DE LA INFECCION CAUSADA POR VRSh | |
| BRPI0912570B8 (pt) | anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos | |
| BR112014023063A2 (pt) | anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos | |
| BR112013002831A2 (pt) | anticorpos direcionados contra a il-17 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |